DK2081551T3 - Dannelse af en tørret rekonstitueret vesikel til farmaceutisk anvendelse - Google Patents

Dannelse af en tørret rekonstitueret vesikel til farmaceutisk anvendelse

Info

Publication number
DK2081551T3
DK2081551T3 DK07818735.8T DK07818735T DK2081551T3 DK 2081551 T3 DK2081551 T3 DK 2081551T3 DK 07818735 T DK07818735 T DK 07818735T DK 2081551 T3 DK2081551 T3 DK 2081551T3
Authority
DK
Denmark
Prior art keywords
formation
pharmaceutical use
dried reconstituted
vesicle
reconstituted vesicle
Prior art date
Application number
DK07818735.8T
Other languages
English (en)
Inventor
Klaus Hellerbrand
Andreas Schuetz
Rainer Sigl
Original Assignee
Scil Technology Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Technology Gmbh filed Critical Scil Technology Gmbh
Application granted granted Critical
Publication of DK2081551T3 publication Critical patent/DK2081551T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
DK07818735.8T 2006-10-06 2007-10-05 Dannelse af en tørret rekonstitueret vesikel til farmaceutisk anvendelse DK2081551T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06021093 2006-10-06
PCT/EP2007/008659 WO2008040556A1 (en) 2006-10-06 2007-10-05 Dried reconstituted vesicle formation for pharmaceutical application

Publications (1)

Publication Number Publication Date
DK2081551T3 true DK2081551T3 (da) 2013-05-06

Family

ID=38910893

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07818735.8T DK2081551T3 (da) 2006-10-06 2007-10-05 Dannelse af en tørret rekonstitueret vesikel til farmaceutisk anvendelse

Country Status (17)

Country Link
US (3) US9526761B2 (da)
EP (2) EP2086507B1 (da)
JP (2) JP5484059B2 (da)
KR (1) KR101333279B1 (da)
CN (3) CN101605534A (da)
CA (1) CA2664637C (da)
CY (1) CY1113934T1 (da)
DK (1) DK2081551T3 (da)
ES (2) ES2400162T3 (da)
HR (1) HRP20130328T1 (da)
PL (1) PL2081551T3 (da)
PT (1) PT2081551E (da)
RS (1) RS52706B (da)
RU (1) RU2443412C2 (da)
SI (1) SI2081551T1 (da)
TW (1) TWI455731B (da)
WO (2) WO2008040556A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258690B2 (en) 2003-03-28 2007-08-21 Relievant Medsystems, Inc. Windowed thermal ablation probe
US8361067B2 (en) 2002-09-30 2013-01-29 Relievant Medsystems, Inc. Methods of therapeutically heating a vertebral body to treat back pain
US6907884B2 (en) 2002-09-30 2005-06-21 Depay Acromed, Inc. Method of straddling an intraosseous nerve
WO2006113586A2 (en) 2005-04-15 2006-10-26 Musculoskeletal Transplant Foundation Vertebral disc repair
WO2008013763A2 (en) 2006-07-25 2008-01-31 Musculoskeletal Transplant Foundation Packed demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation
EP3406210A1 (en) 2008-09-26 2018-11-28 Relievant Medsystems, Inc. Systems and for navigating an instrument through bone
US10028753B2 (en) 2008-09-26 2018-07-24 Relievant Medsystems, Inc. Spine treatment kits
KR101880905B1 (ko) * 2010-04-27 2018-07-23 에스씨아이엘 테크놀로지 게엠베하 안정한 수성 ｍｉａ／ｃｄ－ｒａｐ 제제
US10390877B2 (en) 2011-12-30 2019-08-27 Relievant Medsystems, Inc. Systems and methods for treating back pain
US20130202682A1 (en) * 2012-01-24 2013-08-08 The Trustees Of Columbia University In The City Of New York Synthetic matrix vesicles for biomimetic mineralization
PL2854769T3 (pl) * 2012-07-05 2023-08-07 Taiwan Liposome Company, Ltd. Sposoby leczenia zapalenia stawów
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
WO2014071161A1 (en) 2012-11-05 2014-05-08 Relievant Medsystems, Inc. System and methods for creating curved paths through bone and modulating nerves within the bone
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
US10159646B2 (en) * 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
CA2968478C (en) * 2014-12-18 2021-10-12 Bracco Suisse Sa Targeted gas-filled microvesicles formulation
ES2826896T3 (es) 2015-05-04 2021-05-19 Versantis AG Método para preparar vesículas con gradiente de pH transmembrana
CA2998665A1 (en) * 2015-09-18 2017-03-23 Bionet Pharma Gmbh Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein
WO2017176196A1 (en) * 2016-04-04 2017-10-12 Chalmers Ventures Ab Methods and compositions for the treatment of intervertebral disc herniation
AU2018258070A1 (en) * 2017-04-25 2019-10-24 Adjuvance Technologies, Inc. Triterpene saponin analogues
PT3675816T (pt) * 2017-08-28 2023-05-31 Taiwan Liposome Co Ltd Composições anestésicas de libertação prolongada e métodos de preparação das mesmas
US11389405B2 (en) 2017-09-18 2022-07-19 North Carolina State University Artificial beta cells and methods of use thereof
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
JP7079984B2 (ja) 2018-07-28 2022-06-03 エクソコバイオ インコーポレイテッド エキソソームの凍結乾燥方法
KR102163806B1 (ko) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
KR20210093232A (ko) * 2018-10-09 2021-07-27 더 유니버시티 오브 브리티시 콜롬비아 유기용매와 세제가 없는 형질감염 적격 소포를 포함하는 조성물과 시스템 및 관련 방법
WO2021050767A1 (en) 2019-09-12 2021-03-18 Relievant Medsystems, Inc. Systems and methods for tissue modulation
CN113995852B (zh) * 2021-11-08 2024-01-30 河北大学 Arg-脂质体微囊、微囊包封的鱼精蛋白-siRNA复合体及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (da) * 1977-08-05 1981-02-13 Battelle Memorial Institute
FR2416008A1 (fr) * 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
US4897353A (en) * 1986-03-13 1990-01-30 University Of Southwestern Louisiana Cryogenic protection of phosphofructokinase using amino acids and zinc ions
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
WO1992002208A1 (en) 1990-08-08 1992-02-20 Liposome Technology, Inc. Stable doxorubicin/liposome composition
CA2120197A1 (en) * 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
GB9320668D0 (en) 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
US6066331A (en) * 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
IL115199A (en) * 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AU5702099A (en) * 1998-09-01 2000-03-21 Millennium Pharmaceuticals, Inc. A novel protein related to melanoma-inhibiting protein and uses thereof
EP1025871A1 (en) * 1999-01-28 2000-08-09 F. Hoffmann-La Roche Ag Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair
US7435260B2 (en) * 1999-08-13 2008-10-14 Ferree Bret A Use of morphogenetic proteins to treat human disc disease
DK1244388T3 (da) * 1999-12-06 2007-05-14 Warsaw Orthopedic Inc Indretning til behandling af mellemhvirvelskiver
TWI235066B (en) * 2001-10-03 2005-07-01 Celator Technologies Inc Liposome loading with metal ions
JP2006518701A (ja) * 2002-05-24 2006-08-17 ネオファーム、インコーポレイティッド カルジオリピン組成物、その製造方法及び使用
US7169405B2 (en) * 2003-08-06 2007-01-30 Warsaw Orthopedic, Inc. Methods and devices for the treatment of intervertebral discs
GB2430367B (en) * 2004-03-30 2009-08-05 Ilypsa Inc Ion binding polymers and uses thereof
EP1778309B1 (en) * 2004-05-21 2010-11-17 Synthes GmbH Replacement of nucleus pulposus using a hydrogel
WO2005115438A1 (en) * 2004-05-25 2005-12-08 Stryker Corporation Use of morphogenic proteins for treating cartilage defects
EP1604693A1 (en) * 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
US20060110441A1 (en) * 2004-10-28 2006-05-25 Harry Wong Lyophilized liposome formulations and method
US20110071056A1 (en) * 2009-09-24 2011-03-24 Rajesh K Saini Degradable Surfactants, Including Degradable Gemini Surfactants, and Associated Methods

Also Published As

Publication number Publication date
EP2086507A1 (en) 2009-08-12
PL2081551T3 (pl) 2013-06-28
RU2443412C2 (ru) 2012-02-27
EP2081551B1 (en) 2013-01-23
CY1113934T1 (el) 2016-07-27
US9526761B2 (en) 2016-12-27
US20090285880A1 (en) 2009-11-19
RS52706B (en) 2013-08-30
ES2708851T3 (es) 2019-04-11
US20160220638A1 (en) 2016-08-04
KR101333279B1 (ko) 2013-11-27
KR20090086397A (ko) 2009-08-12
ES2400162T3 (es) 2013-04-08
HRP20130328T1 (hr) 2013-05-31
WO2008040557A1 (en) 2008-04-10
CN102940878A (zh) 2013-02-27
CA2664637C (en) 2013-11-12
TWI455731B (zh) 2014-10-11
SI2081551T1 (sl) 2013-05-31
JP5404402B2 (ja) 2014-01-29
TW200829283A (en) 2008-07-16
CA2664637A1 (en) 2008-04-10
RU2009117170A (ru) 2010-11-20
EP2086507B1 (en) 2018-11-07
WO2008040556A1 (en) 2008-04-10
JP2010505482A (ja) 2010-02-25
EP2081551A1 (en) 2009-07-29
PT2081551E (pt) 2013-02-18
CN101528197B (zh) 2013-02-13
US20090297580A1 (en) 2009-12-03
JP5484059B2 (ja) 2014-05-07
CN101528197A (zh) 2009-09-09
JP2010505785A (ja) 2010-02-25
CN101605534A (zh) 2009-12-16

Similar Documents

Publication Publication Date Title
DK2081551T3 (da) Dannelse af en tørret rekonstitueret vesikel til farmaceutisk anvendelse
LTPA2020501I1 (lt) Pakeistieji enaminokarbonilo junginiai
DK2041139T3 (da) Farmaceutiske forbindelser
DK2399580T3 (da) Farmaceutiske doseringsformer
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
DK1981859T3 (da) Fremstilling af delmopinol
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
ATE483711T1 (de) Spiroindolinonderivate
BRPI0715712A2 (pt) Composição farmacêutica
ATE469905T1 (de) Pyridopyrimidinonderivate
DK1986650T3 (da) Manipulationssikre doserignsformer
BRPI0821831A2 (pt) Compostos inseticidas
ATE512135T1 (de) Spiroindolinonderivate
DK2046767T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2035394T3 (da) 2-pyrazincarboxamidderivater
BRPI0719393A2 (pt) Composição farmacêutica
ATE524477T1 (de) Aziridinylepothilonverbindungen
BRPI0719394A2 (pt) Preparação medicinal sólida
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
DK2018158T3 (da) Ny racecadotril administrationsform
ATE544764T1 (de) 5-hydroxymethyloxazolidin-2-onderivate
DK2271618T3 (da) Farmaceutiske forbindelser
DK2131818T3 (da) Ny doseringsform
DE602007001593D1 (de) Aryl-/alkylvinylsulfon-hyaluronsäurederivate